
-
X4 Pharmaceuticals NasdaqCM:XFOR X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company also develops mavorixafor that is in Phase 3 4WARD clinical trial to evaluate the efficacy, safety, and tolerability of oral, once-daily mavorixafor with or without stable doses of G-CSF in people with congenital, acquired primary autoimmune, or idiopathic CN who are experiencing recurrent and/or serious infections. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications; and with Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand. The company is headquartered in Boston, Massachusetts.
Location: 61 North Beacon Street, Boston, MA, 02134, United States | Website: https://www.x4pharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
11.47M
Cash
86.95M
Avg Qtr Burn
-27.42M
Short % of Float
7.14%
Insider Ownership
2.30%
Institutional Own.
57.33%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Mavorixafor (CXCR4 inhibitor) Details WHIM Syndrome | Approved Quarterly sales | |
Mavorixafor (CXCR4 inhibitor) Details Severe Congenital Neutropenia | Phase 3 Data readout | |
Mavorixafor (CXCR4 inhibitor) Details Renal cell carcinoma, Cancer | Failed Discontinued | |
Mavorixafor (CXCR4 inhibitor) + ibrutinib Details Waldenstrom macroglobulinemia | Failed Discontinued |